HPV16 CTL epitope peptide-activated dendritic cell and natural killer co-culture for therapy of cervical cancer in an animal model

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 12, 2013, Pages 7335-7338

  Hu, Yan Xia ^a   Li, Min ^a   Jia, Xiao Hui ^a   Du, Qu Xiao ^a   Miao, Feng Tai ^a   Yao, Li ^a   Shen, Ji Duo ^b  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Cervical cancer therapy; Dendritic cells; Epitope stimulation; Interaction; Natural killer cells

Indexed keywords

CANCER VACCINE; EPITOPE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; PEPTIDE FRAGMENT; PROTEIN E7;

ANIMAL; C57BL MOUSE; COCULTURE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE MODEL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNIZATION; IMMUNOLOGY; MOUSE; NATURAL KILLER CELL; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE; UTERINE CERVICAL NEOPLASMS;

ANIMALS; CANCER VACCINES; COCULTURE TECHNIQUES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84893403397     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.12.7335     Document Type: Article

References (21)

1. Bellora F, Castriconi R, Dondero A, et al (2010). The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci USA, 107, 21659-64.
2. Boudreau JE, Bridle BW, Stephenson KB, et al (2009). Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther, 17, 1465-72.
3. Degli-Esposti MA, Smyth MJ (2005). Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol, 5, 112-24.
4. Di Nicola M, Zappasodi R, Carlo-Stella C, et al (2009). Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood, 113, 18-27.
5. Eissmann P, Evans JH, Mehrabi M, et al (2010). Multiple mechanisms downstream of TLR-4 stimulation allow expression of NKG2D ligands to facilitate macrophage/NK cell crosstalk. J Immunol, 184, 6901-9.
6. Gasser S, Raulet D (2006). The DNA damage response, immunity and cancer. Semin Cancer Biol, 16, 344-7.
7. Gilboa E (2007). DC-based cancer vaccines. J Clin Invest, 117, 1195-203.
8. Grzywacz B, Miller JS, Verneris MR (2008). Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol, 21, 467-83.
9. Ilett EJ, Prestwich RJ, Melcher AA. (2010). The evolving role of dendritic cells in cancer therapy. Expert Opin Biol Ther, 10, 369-79.
10. Karimi K, Boudreau JE, Fraser K, et al (2008). Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gammaproducing NK cells. Mol Ther, 16, 411-8.
11. Morandi B, Mortara L, Chiossone L, et al (2012). Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS One, 7, e39170.
12. Nakai N, Hartmann G, Kishimoto S, et al (2010). Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res, 23, 607-19.
13. Osada T, Clay T, Hobeika A, et al (2006). NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother, 55, 1122-31.
14. Petersen TR, Sika-Paotonu D, Knight DA, et al (2011). Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines. PLoS One, 6, e17657.
15. Shanker A (2010). Adaptive control of innate immunity. Immunol Lett, 131, 107-12.
16. Shanker A, Buferne M, Schmitt-Verhulst AM (2010). Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology, 129, 41-54.
17. Shanker A, Verdeil G, Buferne M, et al (2007). CD8 T cell help for innate antitumor immunity. J Immunol, 179, 6651-62.
18. Shen L, Evel-Kabler K, Strube R, et al (2004). Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol, 22, 1546-53.
19. van den Broeke LT, Daschbach E, Thomas EK, et al (2003). Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol, 171, 5842-52.
20. Van Elssen CH, Vanderlocht J, Oth T, et al (2011). Inflammationrestraining effects of prostaglandin E2 on natural killerdendritic cell (NK-DC) interaction are imprinted during DC maturation. Blood, 118, 2473-82.
21. Viaud S, Terme M, Flament C, et al (2009). Dendritic cellderived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One, 4, e4942.